Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...
Adalytics rocked the ad world with a scathing report on industry brand safety, leading to backlash against monitoring tools like DoubleVerify and IAS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback